
News|Articles|June 25, 2026
CGMs, Automated Insulin Delivery Support Personalized Diabetes Treatment
Author(s)Ashley Gallagher, MA
Pharmacists leverage CGM and automated insulin delivery to personalize diabetes care, prevent errors, and expand equitable access to technology.
Advertisement
Advertisement
The landscape of diabetes care is undergoing a transformation as fingersticks and episodic monitoring give way to real-time data and automated logic. For pharmacists, this evolution represents a shift toward a more proactive, data-driven role in patient management. At the heart of this shift are continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems, technologies that are moving from specialized tools for the few to routine components of care for the many.1,2
Related to this article

Our hosts explore why ketone monitoring matters, what pharmacists should know about Libre Duo, and how patient education can support proactive care management.

Despite Gazyva being the first drug accepted to treat this type of nephropathy, it’s already approved for a host of other conditions.

The Milken Institute released survey results alongside new data regarding the need for pharmacists in extending effective GLP-1 care.

Findings from a meta-analysis of over 125 clinical trials led the agency to require a class-wide label change.

An abstract from the American Heart Association's Scientific Sessions 2026 reveals the continuous expansion of the GLP-1 medication class.

Owners believe clean plan-to-patient matching before January 1 is one of the simplest ways to protect cash flow in 2027.

The PAHO confirmed the loss after more than 12 months of continuous transmission, putting renewed focus on pharmacists' role in closing vaccination gaps.
Advertisement
Advertisement

